{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:54:45Z","timestamp":1773820485511,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Emerging evidence suggests a role of neuronal autoantibodies (nAbs) for long-term stroke outcomes. However, data remain limited and many domains unexamined. We present a comprehensive analysis of nAbs and their association with a broad range of outcome measures at multiple timepoints in the six months following moderate stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this explorative analysis of the multicenter, randomized-controlled\n                      <jats:italic>PHYS-STROKE<\/jats:italic>\n                      trial, serum samples from stroke patients were tested for 40 nAbs at baseline (5\u201345 days post-stroke), post-intervention (4 weeks after baseline), and at three and six months after stroke. Generalized estimating equation (GEE)-models were used to evaluate the dynamics of nAbs over time. Multiple linear regression models were applied to investigate the prognostic role of nAbs on various outcomes at three and six months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred stroke patients (41% female; mean age: 69 \u00b1 12 years, median acute National Institutes of Health Stroke Scale: 8) were enrolled. Cell-based seroreactivity decreased from baseline to six months (39 of 183 patients [21%]\n                      <jats:italic>vs.<\/jats:italic>\n                      18 of 137 patients [13%]). while tissue-based reactivity increased (4 of 183 patients [2%]\n                      <jats:italic>vs.<\/jats:italic>\n                      9 of 137 patients [7%]). The GEE applied to the imputed dataset indicated a statistically significant decreased likelihood of seroreactive nAbs in cell-based assays from baseline to six months (\n                      <jats:italic>95%CI<\/jats:italic>\n                      = 0.36 to 0.98;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.041), while tissue-based analyses showed an inverse effect for the same time period (\n                      <jats:italic>95%CI<\/jats:italic>\n                      = 1.11 to 8.51;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.032). The most frequently detected antibody was anti-N-Methyl-D-Aspartate receptor GluN1 (NMDAR (IgM, IgA, IgG), 30 patients [15.1%]). Baseline nAB seropositivity was associated with worse depression scores (\n                      <jats:italic>95%CI<\/jats:italic>\n                      = 0.03 to 7.82;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.048) and poorer subjective mobility (\n                      <jats:italic>95%CI=<\/jats:italic>\n                      0.04 to 0.99;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.033) at six months post-stroke. NMDAR-antibodies at baseline were linked to a lower subjective overall health rating (\n                      <jats:italic>95%CI<\/jats:italic>\n                      = -17.96 to -0.16;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.046) and lower maximum walking speed (\n                      <jats:italic>95%CI<\/jats:italic>\n                      = -0.57 to -0.03;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.027) at six months. No associations were found with outcomes at three months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antibody seropositivity was associated with poorer outcomes in certain neuropsychological and motor outcome measures at six but not three months post-stroke. These findings require confirmation in larger cohorts and emphasize the need for future studies with longer follow-up periods in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>clinicaltrials.gov NCT01953549.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1678840","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:55:44Z","timestamp":1773816944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuronal autoantibodies associated with poorer neuropsychological and motor outcomes 6 months after stroke: results from the PHYS-STROKE trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Charlotte","family":"Pietrock","sequence":"first","affiliation":[{"name":"Center for Stroke Research Berlin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Department of Neurology with Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu, and Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Neumann","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Rentzsch","sequence":"additional","affiliation":[{"name":"Clinical Immunological Laboratory Prof. h.c. (RCH) Dr. med. Winfried St\u00f6cker","place":["Gro\u00df Gr\u00f6nau, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[{"name":"Department of Neurology with Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu, and Berlin Institute of Health","place":["Berlin, Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE)","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Neurology with Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu, and Berlin Institute of Health","place":["Berlin, Germany"]},{"name":"Center for Stroke Research Berlin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Neuroscience Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Endres","sequence":"additional","affiliation":[{"name":"Department of Neurology with Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu, and Berlin Institute of Health","place":["Berlin, Germany"]},{"name":"Center for Stroke Research Berlin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE)","place":["Berlin, Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK)","place":["Berlin, Germany"]},{"name":"German Center for Mental Health (DZPG)","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Heinrich","family":"Nave","sequence":"additional","affiliation":[{"name":"Department of Neurology with Experimental Neurology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu, and Berlin Institute of Health","place":["Berlin, Germany"]},{"name":"Center for Stroke Research Berlin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK)","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Feigin","year":"2024","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029606","article-title":"Burden of stroke in europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years","volume":"51","author":"Wafa","year":"2020","journal-title":"Stroke"},{"key":"B3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000546","article-title":"Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease","volume":"31","author":"Ehrenreich","year":"2018","journal-title":"Curr Opin neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.24189","article-title":"Seroprevalence of autoantibodies against brain antigens in health and disease","volume":"76","author":"Dahm","year":"2014","journal-title":"Ann Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1491880","article-title":"Antibodies against neuronal surface antigens in acute stroke: a systematic review and meta-analysis","volume":"16","author":"Paolucci","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.008323","article-title":"Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke","volume":"46","author":"Zerche","year":"2015","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09470-2","article-title":"Antibodies against neural antigens in patients with acute stroke: joint results of three independent cohort studies","volume":"266","author":"Royl","year":"2019","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000212","article-title":"Serum anti-NMDA (N-methyl-D-aspartate)-receptor antibodies and long-term clinical outcome after stroke (PROSCIS-B)","volume":"50","author":"Sperber","year":"2019","journal-title":"Stroke"},{"key":"B10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41398-020-00989-x","article-title":"Cognitive impact of neuronal antibodies: encephalitis and beyond","volume":"10","author":"Gibson","year":"2020","journal-title":"Trans Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz083","article-title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","volume":"30","author":"Bartels","year":"2019","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2049","article-title":"Association between neuronal autoantibodies and cognitive impairment in patients with lung cancer","volume":"7","author":"Bartels","year":"2021","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.120","article-title":"High prevalence of NMDA receptor IgA\/IgM antibodies in different dementia types","volume":"1","author":"Doss","year":"2014","journal-title":"Ann Clin Trans Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11203-x","article-title":"Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)","volume":"269","author":"Sperber","year":"2022","journal-title":"J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.05.011","article-title":"Autoantibodies against the NMDAR subunit NR1 are associated with neuropsychiatric outcome after ischemic stroke","volume":"96","author":"Deutsch","year":"2021","journal-title":"Brain behav immun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02744-w","article-title":"Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke","volume":"30","author":"Arlt","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2023.100705","article-title":"Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke","volume":"34","author":"Sperber","year":"2023","journal-title":"Brain behavi Immun - Health"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.001235","article-title":"Stroke patients develop antibodies that react with components of N-methyl-D-aspartate receptor subunit 1 in proportion to lesion size","volume":"44","author":"Kalev-Zylinska","year":"2013","journal-title":"Stroke"},{"key":"B19","author":"Nave","year":""},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-45","article-title":"Physical fitness training in Subacute Stroke (PHYS-STROKE) - study protocol for a randomised controlled trial","volume":"15","author":"Fl\u00f6el","year":"2014","journal-title":"Trials"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-197","article-title":"Biomarkers and perfusion - training-induced changes after stroke (BAPTISe): protocol of an observational study accompanying a randomized controlled trial","volume":"11","author":"Nave","year":"2013","journal-title":"BMC Neurol"},{"key":"B23","volume-title":"R: A language and environment for statistical computing. R Foundation for Statistical Computing","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/17474930211006286","article-title":"Physical Fitness Training in Patients with Subacute Stroke (PHYS-STROKE): Safety analyses of a randomized clinical trial","volume":"17","author":"Rackoll","year":"2022","journal-title":"Int J Strok"},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.pathol.1.110304.100100","article-title":"Inflammation and atherosclerosis","volume":"1","author":"Hansson","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.17.2.241","article-title":"Screening for depression in stroke patients: The reliability and validity of the Center for Epidemiologic Studies Depression Scale","volume":"17","author":"Shinar","year":"1986","journal-title":"Stroke"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:55:47Z","timestamp":1773816947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1678840"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1678840","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1678840"}}